IDH1 and central nervous system cancer: In glioma cases, IDH genes can be mutated in 73% of patients, with the most common mutation occurring at arginine 132 (R132).13 These mutated IDH enzymes have distinct metabolic and epigenetic characteristics and respond differently to treatments,14 leading to improved patient prognoses compared to IDH1-wt.